TNXP Long Call Strategy
TNXP (Tonix Pharmaceuticals Holding Corp.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication.
TNXP (Tonix Pharmaceuticals Holding Corp.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $196.6M, a beta of 1.69 versus the broader market, a 52-week range of 11.6-69.97, average daily share volume of 414K, a public-listing history dating back to 2012, approximately 81 full-time employees. These structural characteristics shape how TNXP stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.69 indicates TNXP has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a long call on TNXP?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
Current TNXP snapshot
As of May 15, 2026, spot at $15.68, ATM IV 108.90%, IV rank 29.89%, expected move 31.22%. The long call on TNXP below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this long call structure on TNXP specifically: TNXP IV at 108.90% is on the cheap side of its 1-year range, which favors premium-buying structures like a TNXP long call, with a market-implied 1-standard-deviation move of approximately 31.22% (roughly $4.90 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated TNXP expiries trade a higher absolute premium for lower per-day decay. Position sizing on TNXP should anchor to the underlying notional of $15.68 per share and to the trader's directional view on TNXP stock.
TNXP long call setup
The TNXP long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With TNXP near $15.68, the first option leg uses a $15.68 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed TNXP chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 TNXP shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $15.68 | N/A |
TNXP long call risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
TNXP long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on TNXP. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use long call on TNXP
Long calls on TNXP express a bullish thesis with defined risk; traders use them ahead of TNXP catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
TNXP thesis for this long call
The market-implied 1-standard-deviation range for TNXP extends from approximately $10.78 on the downside to $20.58 on the upside. A TNXP long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current TNXP IV rank near 29.89% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on TNXP at 108.90%. As a Healthcare name, TNXP options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to TNXP-specific events.
TNXP long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. TNXP positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move TNXP alongside the broader basket even when TNXP-specific fundamentals are unchanged. Long-premium structures like a long call on TNXP are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current TNXP chain quotes before placing a trade.
Frequently asked questions
- What is a long call on TNXP?
- A long call on TNXP is the long call strategy applied to TNXP (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With TNXP stock trading near $15.68, the strikes shown on this page are snapped to the nearest listed TNXP chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are TNXP long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the TNXP long call priced from the end-of-day chain at a 30-day expiry (ATM IV 108.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a TNXP long call?
- The breakeven for the TNXP long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current TNXP market-implied 1-standard-deviation expected move is approximately 31.22%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on TNXP?
- Long calls on TNXP express a bullish thesis with defined risk; traders use them ahead of TNXP catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current TNXP implied volatility affect this long call?
- TNXP ATM IV is at 108.90% with IV rank near 29.89%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.